Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $58.7552W HIGH $89.77
Volume
1.17 M
Value Traded
237.35 M
Short % Float
3.76%
+1.94%Week
+0.57%1 Month
+1.3%3 Month
-10.44%6 Month
+1.95%5 Year
+1.95%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
29.55 B
EPS (TTM)
4.39
P/E Ratio
14.92
Ent. Value
37.64 B
Total Shares
451.69 M
Float Shares
450.24 M
Insiders
0.32%
Institutions
92.08%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
GEHC Catalyst Timeline
Dated clinical, regulatory and corporate events for GE HealthCare Technologies Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for GE HealthCare Technologies Inc.
75Total events
12Upcoming
25Tier-1 (high impact)
2023 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Product LaunchPost-Market
GE HealthCare announces CareIntellect for Operations, available for purchase
●Management ChangeCorporate
William Grogan appointed Chief Financial Officer, effective September 14, 2026
◆Management ChangeCorporate
Jay Saccaro to step down as CFO; George Newcomb appointed interim CFO
▲Quarterly UpdateCorporate
Preliminary Q2 2026 results: revenue growth 5.7%, organic growth 3.5%
◆Management ChangeCorporate
Phil Rackliffe appointed President and CEO of Advanced Imaging Solutions
▲Partnership / LicenseCorporate
Expanded collaboration with DeepHealth to extend global access to AI-powered breast cancer screening solutions
breast cancer screeningsource ↗
●Oral PresentationPresentation
Showcase latest women's health innovations at Society of Breast Imaging Annual Symposium
breast cancer screeningsource ↗
◆Quarterly UpdateCorporate
Recast financial results for new segment structure expected in Q2 2026 earnings release
▲Partnership / LicenseCorporate
GE HealthCare announces lead industrial role in COMPASS consortium
cardio-oncologysource ↗
▲Partnership / LicenseCorporate
GE HealthCare to lead industrial role in EU-funded IHI consortium for cardio-oncology care
cardio-oncologysource ↗
▲Partnership / LicenseCorporate
Agreement with Gentuity to connect customers with Gentuity HF-OCT and Vis-Rx PRIME Micro-Imaging Catheter
cardiac catheterizationsource ↗
▲Product LaunchReadyFixPost-Market
U.S. launch of ReadyFix fleet management solution for MAC VU360 ECG workstations
cardiac caresource ↗
●Oral PresentationPresentation
Showcase of cardiology portfolio at ACC.26 conference
cardiologysource ↗
▲FDA ApprovalSPECTApprovedFDA Decision
FDA 510(k) clearance for Photonova Spectra photon-counting CT
◆Oral PresentationPresentation
GE HealthCare to showcase AI and digital leadership at HIMSS 2026
▲Partnership / LicenseCorporate
BARDA contract expansion of approximately $35 million for AI-powered ultrasound
trauma care and emergency preparednesssource ↗
◆Oral PresentationPresentation
GE HealthCare management to present at upcoming investor conferences
▲Product LaunchReadyFixPost-Market
GE HealthCare launches ReadyFix fleet management solution in the United States
▲FDA Filing AcceptedRegulatory Filing
FDA 510(k) clearance for Allia Moveo
interventional imagingsource ↗
▲Product LaunchPost-Market
First global installation of Allia Moveo at Hôpital Marie-Lannelongue
interventional imagingsource ↗
◆Oral PresentationPresentation
GE HealthCare management to present at JP Morgan 44th Annual Healthcare Conference
●Oral PresentationPresentation
GE HealthCare showcases innovations at RSNA 2025 Annual Meeting
▲FDA ApprovalFlyrcadoApprovedFDA Decision
FDA approval of Flyrcado (flurpiridaz F 18) injection for PET MPI
coronary artery diseasesource ↗
▲FDA ApprovalFDA Decision
FDA Premarket Authorization for Pristina Recon DL
mammography image reconstructionsource ↗
▼Equity OfferingCorporate
Pricing of upsized secondary offering of 15,000,000 shares at $86.00 per share
Past FDA Catalysts and PDUFA Decisions
How GEHC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-24 | Vizamyl (flutemetamol f-18) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C56 / 100
Pipeline Score
$2.2B
Pipeline Value
Not rated
Valuation Signal
9
Drugs Scored
-
rNPV / MCap
Top 10%
Mid Cap(rank 67 of 658)
Percentile Rank
GE HealthCare Technologies Inc. carries a moderate pipeline score (56/100), with $2.6B risk-adjusted pipeline value, led by PET MPI in Coronary Artery Disease (CAD) (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PET MPI Small moleculeCompletedNCT03354273 | Coronary Artery Disease (CAD) | Phase 3 | COMPLETED | 730 | May 5, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every GEHC program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lobo KevinDirector | Buy | 10,000 14,363 held | $64.18 | 05/22/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GEHC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.4 % (-71.4 %) | 9.60 M | 150.00 K | -25% ( -50.00 K) |
GEHC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-27 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GEHC ranks across every disease it competes in
Competitive Position is a premium feature
See how GEHC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGEHC News
GEHC▲ +1.9%today
GE HealthCare to announce third quarter 2026 results on October 28, 2026
GE HealthCare will announce its third quarter 2026 financial results on October 28, 2026. The announcement will occur before the market opens, followed by a conference call and webcast at 8:30 a.m. ET. This event allows investors to gain insights into the company's performance.
Read more →GEHCGE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.
GE HealthCare has announced its plan to acquire SOFIE Biosciences for $945 million in cash. This acquisition aims to enhance GE HealthCare's footprint in the PET radiopharmaceutical supply chain in the U.S. The transaction is anticipated to close in the first half of 2027, pending regulatory approvals.
Read more →GEHCGE HealthCare announces cash dividend increase for third quarter of 2026
GE HealthCare Technologies Inc. has announced a cash dividend of $0.04 per share for the third quarter of 2026, marking a 14% increase from the previous quarter. This dividend will be payable on November 13, 2026, to shareholders on record as of October 23, 2026. The announcement reflects the company's strong financial performance.
Read more →GEHCGE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors
GE HealthCare has appointed Pascal Desroches, CFO of AT&T, to its Board of Directors, effective January 4, 2027. Desroches has over 30 years of experience in finance and governance, which is expected to significantly benefit the company. His expertise in large-scale technology and digital transformation will be a valuable asset.
Read more →GEHCGE HealthCare Announces CareIntellect for Operations, Helping Health Systems Optimize Resources and Expand Access to Care
GE HealthCare has launched CareIntellect™ for Operations, an AI-driven SaaS application aimed at assisting health systems in predicting capacity constraints up to 72 hours in advance. This tool analyzes various operational data points, including bed availability and staffing, to provide insights into potential bottlenecks. The initiative is expected to optimize resource allocation and improve patient care access.
Read more →GEHCGE HealthCare’s Photonova™ Spectra gains CE Mark, expanding international access
GE HealthCare has received CE Mark approval for its Photonova Spectra, an advanced photon-counting computed tomography system. This regulatory achievement allows for broader access and clinical adoption in CE Mark-observing countries. The approval emphasizes GE HealthCare's dedication to innovation in the field of computed tomography.
Read more →GEHCGE HealthCare management to present at upcoming investor conference
GE HealthCare has announced that its management team will present at the Wells Fargo 21st Annual Health Conference on September 9, 2026. The presentation is scheduled for 10:15 am ET/9:15 am CT. A webcast of the event will be available on the company's investor relations website.
Read more →GEHCGE HealthCare appoints William Grogan as Chief Financial Officer
GE HealthCare has appointed William Grogan as Chief Financial Officer, effective September 14, 2026. He succeeds Jay Saccaro, who has taken on a new role outside the medical technology sector. George Newcomb will remain as interim CFO and continue as Controller and Chief Accounting Officer during this transition.
Read more →GEHC▲ +12.2%on this news
GE HealthCare reports second quarter 2026 financial results
GE HealthCare reported strong financial results for the second quarter of 2026, highlighting record orders and backlog. The company experienced growth in orders across all segments, demonstrating effective commercial execution. CEO Peter Arduini emphasized the focus on returning the Patient Care Solutions business to growth and profitability.
Read more →GEHCGE HealthCare announces CFO transition; reports preliminary second quarter 2026 financial results and reaffirms guidance reflecting business momentum
GE HealthCare has announced the departure of CFO Jay Saccaro, who will transition to a role outside the medical technology sector. George Newcomb, the current Controller and Chief Accounting Officer, has been appointed as the interim CFO. Saccaro will assist in the transition until August 14, 2026, while the company reaffirms its positive business outlook.
Read more →GEHCGE HealthCare introduces MIM Anyware to extend remote access to imaging data and optimize clinical collaboration
GE HealthCare has launched MIM Anyware, a remote access platform that allows secure access to imaging data via a web browser. This innovation eliminates the need for local software installation, facilitating collaboration among healthcare professionals. MIM Anyware aims to enhance clinical decision-making by providing authorized users with access to MIM software applications from any location.
Read more →GEHCCatholic Health and GE HealthCare partner to expand patient access across Long Island
Catholic Health and GE HealthCare have formed a 10-year strategic partnership, valued at approximately $500 million. This collaboration aims to enhance access to advanced imaging, precision diagnostics, and AI-enabled technology throughout Catholic Health. The initiative is designed to support innovative and compassionate patient-centered care across Long Island.
Read more →GEHCGE HealthCare to announce second quarter 2026 results on July 29, 2026
GE HealthCare will announce its second quarter 2026 financial results on July 29, 2026, before the market opens. The management team will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day. Investors can access the live webcast through the company's investor relations website.
Read more →GEHCGE HealthCare announces cash dividend for second quarter of 2026
GE HealthCare has announced a cash dividend for the second quarter of 2026. This decision reflects the company's ongoing commitment to returning value to its shareholders. However, the article does not provide further details on the dividend amount or other financial implications.
Read more →GEHCESTRO 2026 Congress: GE HealthCare to spotlight AI-enabled solutions to advance precision care across radiation therapy and image-guided interventions
GE HealthCare is set to showcase its AI-enabled solutions at the ESTRO 2026 Congress. The focus will be on advancing precision care in radiation therapy and image-guided interventions. This event highlights the company's commitment to integrating technology into healthcare practices.
Read more →GEHCGE HealthCare next-gen SIGNA MR technology helps advance research discovery and translate innovation into clinical impact
GE HealthCare has introduced next-generation SIGNA MR technology aimed at enhancing research discovery and translating innovations into clinical applications. The new technology is designed to improve imaging capabilities, which could lead to better patient outcomes. However, specific details about the technology's features and clinical impact are not provided.
Read more →GEHC▼ -13.2%on this news
GE HealthCare announces executive team and operational updates to enhance execution, accelerate innovation, and drive growth
GE HealthCare has announced significant changes to its executive team and operational structure to enhance growth and innovation. Phil Rackliffe has been appointed CEO of the new Advanced Imaging Solutions segment, while Catherine Estrampes will lead Global Markets. These changes aim to streamline operations and improve patient care, although they come with the departure of a key leader.
Read more →GEHC▼ -13.2%on this news
GE HealthCare reports first quarter 2026 financial results
GE HealthCare reported its first quarter 2026 financial results, showing a revenue increase of 7.4% to $5.1 billion, driven by strong performance in Pharmaceutical Diagnostics and Imaging. However, profitability was affected by supplier issues and rising costs, prompting a cautious reduction in profit outlook. The company remains optimistic about future growth through innovation and customer demand.
Read more →GEHCGE HealthCare management to present at upcoming investor conferences
GE HealthCare has announced that its management team will present at two upcoming investor conferences: the Bank of America's 2026 Health Care Conference on May 12 and the Jefferies Global Healthcare Conference on June 3. Webcasts for these events will be available on the GE HealthCare website. The company continues to be a leader in healthcare solutions.
Read more →GEHCGE HealthCare expands mammography collaboration with RadNet’s DeepHealth subsidiary to extend global access to DeepHealth’s AI-powered breast cancer screening solutions
GE HealthCare has expanded its collaboration with DeepHealth to enhance AI-powered mammography tools. This partnership aims to improve breast cancer screening globally by integrating advanced technologies into existing workflows. The initiative builds on previous efforts to increase detection rates and operational efficiency in breast imaging. The collaboration was announced at the Society of Breast Imaging Annual Symposium.
Read more →About GE HealthCare Technologies Inc.
Headquarters500 WEST MONROE STREET, CHICAGO, IL, 60661
BIOPHARMAWATCH ELITE PLUS
Trade the next GEHC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime